Lyell Immunopharma (LYEL) Selling, General & Administrative (2020 - 2026)

Lyell Immunopharma (LYEL) Selling, General & Administrative (2020 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) SG&A (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -10.08 Mn
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - 2.17 Mn
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 555.10 Mn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 493.70 Mn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 647.70 Mn
7 Belite Bio 61.40 Bn 61.40 Bn - 17.02 Mn
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn -355.00 Mn
9 Revolution Medicines 37.37 Bn 37.37 Bn - 101.25 Mn
10 Lyell Immunopharma 276.08 Mn 276.08 Mn - 9.56 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 9.56 Mn
Dec 31, 2025 10.62 Mn
Sep 30, 2025 10.69 Mn
Jun 30, 2025 9.79 Mn
Mar 31, 2025 14.05 Mn
Dec 31, 2024 14.52 Mn
Sep 30, 2024 11.77 Mn
Jun 30, 2024 12.26 Mn
Mar 31, 2024 13.49 Mn
Dec 31, 2023 13.17 Mn
Sep 30, 2023 15.51 Mn
Jun 30, 2023 19.03 Mn
Mar 31, 2023 19.28 Mn
Dec 31, 2022 26.35 Mn
Sep 30, 2022 26.08 Mn
Jun 30, 2022 30.45 Mn
Mar 31, 2022 34.42 Mn
Dec 31, 2021 31.87 Mn
Sep 30, 2021 21.24 Mn
Jun 30, 2021 19.11 Mn